9 results about "Negative strand" patented technology

The present invention provides a temperature-sensitive negative-strand RNA virus or virus vector and an RNA genome thereof. According to the invention, provided is a negative-strand RNA virus or virus vector having a negative-strand RNA genome wherein the phosphoprotein (P protein) on the RNA genome has an amino acid mutation(s) corresponding to a substitution(s) in an amino acid(s) of the P protein corresponding to one or more or all of D433, R434, and K437 and optionally further has an amino acid mutation corresponding to a further amino acid substitution in an amino acid of the P protein corresponding to L511.

A method, device, medium and program for detecting mutations on the basis of methylation data. The method comprises obtaining methylation data of a sample to be tested; on the basis of the methylation data, obtaining base composition data of a 3-base genome after chemical or enzymatic conversion; on the basis of the base composition data of the 3-base genome after chemical or enzymatic conversion, determining base composition data of a 4-base genome before chemical or enzymatic conversion according to the complementary base-pairing relationship between a positive strand and a negative strand, and / or the corresponding relationship between genotypes before and after chemical or enzymatic conversion; on the basis of the base composition data of the 4-base genome, identifying candidate mutation sites; and filtering the candidate mutation sites to generate detection results relating to single nucleotide variation mutation sites. According to the method, the single nucleotide variations can be detected from whole genome methylation data, and the accuracy of detection for low abundance mutations can be significantly improved.

The application discloses a library sequencing method for determining methylation difference of positive and negative strands of DNA molecules. The application provides a library sequencing method for determining methylation difference of positive and negative strands of DNA molecules, comprising the following steps: 1) using molecular tags UMI to label positive and negative strands of a plurality of DNA double-stranded molecules to obtain a DNA molecule library labeled with molecular tags; 2) performing bisulfite conversion on DNA molecules in the DNA molecule library, converting unmethylated modified C bases in the DNA molecules into U bases to obtain converted DNA molecules; 3) sequentially performing PCR amplification, constructing a sequencing library and sequencing on the converted DNA molecules; and determining the difference in methylation modification of positive and negative strands of the same DNA molecule. Compared with traditional whole genome methylation sequencing, the application can more accurately detect the methylation difference of DNA molecules, and more accurately detect the dynamic change of methylation.

The embodiment of the invention relates to a method, a device, equipment and a product for determining the miss probability of a probe sequence. The method includes constructing a first genome comprising at least one of a low methylation positive strand, a low methylation negative strand, a high methylation positive strand, and a high methylation negative strand. The method also includes determining an off-target probability of the probe sequence based on the constructed first genome. Through the method, the accuracy and sensitivity of off-target detection of the probe sequence are improved, false matching or missing detection is effectively avoided, and a basis is provided for specific control of probe sequence design.

Macrophages (Mφ) are crucial for pathogen detection and elimination, and also serve as a microenvironment for replication of multiple infectious pathogens. This delicate balance between viral replication and antiviral response remains largely unknown at the molecular level. Addressing this issue is physiologically important given the persistent threat posed by emerging viral pathogens. Here, we demonstrate that GAS7 expression within macrophages restricts the replication of viral pathogens belonging to all major viral groups. We show that the antiviral activity of GAS7 exists even under conditions where the classical antiviral response mediated by type I interferon is neutralized. In particular, we show that in human monocyte-derived macrophages, silencing of GAS7 boosts the replication of multiple viral pathogens representing most relevant viral groups. These include the retroviruses HIV-1 (human immunodeficiency virus type 1) and HIV-2 (human immunodeficiency virus type 2), the RNA viruses Zika virus (positive-sense single-stranded RNA), Sindbis virus (single-stranded positive-sense RNA), Sendai virus (negative-sense single-stranded RNA), VSV virus (negative-sense single-stranded RNA), and measles virus (negative-sense single-stranded RNA), and the DNA virus HSV-1 virus (double-stranded DNA). Importantly, the antiviral activity of GAS7 is present even under conditions where type I interferon is neutralized by the addition of the B18R protein (which efficiently blocks the type I receptor). Furthermore, the inventors demonstrate that by forcing macrophages to overexpress GAS7, they are further protected from HIV-1 infection compared to cells expressing this factor at normal levels. Therefore, the present invention relates to the modulation of GAS7 expression and / or activity for modulating viral replication in macrophage populations.

The present application relates to the field of proteins, in particular to a protein combination for detecting ADAMTS13 activity and application thereof.The protein combination for detecting ADAMTS13 activity provided by the present application is composed of two protein subchains Chain A and Chain B, wherein Chain A comprises a circularly arranged GFP as shown in SEQ ID NO.1, a V Part1 of a vWF variant as shown in SEQ ID NO.2 and a negative chain polypeptide as shown in SEQ ID NO.5; Chain B comprises a nanobody as shown in SEQ ID NO.6, a V Part2 of a vWF (D1596-R1668) variant as shown in SEQ ID NO.3 and a positive chain polypeptide as shown in SEQ ID NO.4.The protein combination for detecting ADAMTS13 activity provided by the present application can directly determine the ADAMTS13 enzyme activity in a blood sample, a biological sample or a chemical sample, and is suitable for clinical point-of-care testing, biological sample screening and drug development scenarios.

To develop novel therapeutic techniques that do not pose the risk of genotoxicity to help infertility patients. [Solution] A single-stranded negative-strand RNA viral vector containing a nucleic acid sequence encoding a protein associated with the formation or development of germ cells, or a pharmaceutical composition for preventing or treating infertility containing an RNA molecule encoding the protein, is provided.

This invention discloses a Zika virus-inhibiting siRNA-B and its applications, belonging to the field of biotechnology. The sequence of the siRNA-B is as follows: positive strand: 5'-UGUGGUGAAAUCCAUGGUUUC-3'; negative strand: 5'-GAAACCAUGGAUUUCACCACA-3'. Compared with the known vsiRNA-1 sequence in the prior art, the vsiRNA-B provided by this invention has a better inhibitory effect on Zika virus, providing a more effective drug for the treatment of Zika virus-related diseases.

The invention relates to the field of proteins, in particular to a protein for detecting ADAMTS13 activity and application of the protein. The protein for detecting the activity of the ADAMTS13 at least comprises A1) a nano antibody as shown in SEQ ID NO. 1; a) is a vWF (D1596-R1668) variant as shown in SEQ ID NO.2, A3) is a positive chain polypeptide as shown in SEQ ID NO.3, A4) is a negative chain polypeptide as shown in SEQ ID NO.4, and A5) is annularly arranged GFP (cpGFP) as shown in SEQ ID NO.6. The protein for detecting the activity of ADAMTS13 can directly measure the activity of ADAMTS13 enzyme in a blood sample, a biological sample or a chemical sample, and is suitable for clinical point-of-care testing (POCT), biological sample screening and drug research and development scenes.